Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer.

Clinical lung cancer - 1 Mar 2018

Kim Edward, Feldman Rebecca, Wistuba Ignacio I

Abstract excerpt

Mutations in the epidermal growth factor receptor (EGFR) are important drivers of non-small-cell lung cancer (NSCLC) and have led to the emergence of EGFR-targeted therapies as critical treatment options for NSCLC. Although these agents have shown clinical activity in NSCLC patients, acquired resistance to EGFR-targeted agents is inevitable. Therefore, the ability to conveniently biopsy patient tumors is of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Liquid Biopsy

Share to Lung Neoplasms

Share to Pathology, Molecular

Source

Identifiers

PMID: 28935493
DOI: 10.1016/j.cllc.2017.08.001

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer.PMID 28935493Read ↗

Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era.Semantic proximity Read ↗

Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.Semantic proximity Read ↗

Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.Semantic proximity Read ↗

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC.Semantic proximity Read ↗

The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC.Semantic proximity Read ↗

EGFR mutation testing from liquid biopsy of non-small cell lung cancer at the Institute for Oncology and Radiology of Serbia.Semantic proximity Read ↗

Epidermal growth factor receptor T790M testing in progressed lung cancer: A review of sensitive methods for analysis of tissue and liquid biopsy samples.Semantic proximity Read ↗

Are liquid biopsies a surrogate for tissue EGFR testing?Semantic proximity Read ↗

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.Semantic proximity Read ↗

Liquid biopsy and tissue biopsy for the detection of EGFR mutations in patients with stage III non-small-cell lung cancer: an observational real-world study.Semantic proximity Read ↗

The evolving role of liquid biopsy in lung cancer.Semantic proximity Read ↗

EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.